Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-search-preview· OpenAIHugging Face LMArena Search Arena 24K

DNA damage NF-κB cancer

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with gpt-4o-search-preview-high-loc’s answer.
  1. User

    DNA damage NF-κB cancer

  2. Assistant

    DNA damage triggers a complex cellular response involving the activation of nuclear factor kappa B (NF-κB), a transcription factor that plays a pivotal role in inflammation, cell survival, and proliferation. This activation is particularly significant in the context of cancer, as it can influence tumor progression and resistance to therapies.

    Mechanism of NF-κB Activation by DNA Damage:

    When DNA double-strand breaks (DSBs) occur, the ataxia telangiectasia mutated (ATM) kinase is activated. ATM then phosphorylates the NF-κB essential modulator (NEMO), leading to the activation of the IκB kinase (IKK) complex. This activation results in the degradation of IκB proteins, freeing NF-κB to translocate into the nucleus and initiate the transcription of target genes. This pathway underscores the intricate link between DNA damage and NF-κB activation[1].

    Implications in Cancer Progression and Therapy Resistance:

    The activation of NF-κB in response to DNA damage can promote the expression of anti-apoptotic genes, inflammatory cytokines, and oncogenic microRNAs. This expression contributes to cancer cell survival, proliferation, and metastasis. Notably, NF-κB activation has been associated with resistance to chemotherapeutic agents and radiation therapy, as it helps cancer cells evade apoptosis and adapt to genotoxic stress[2].

    Therapeutic Considerations:

    Targeting the DNA damage-induced NF-κB signaling pathway presents a promising strategy to enhance the efficacy of cancer treatments. By inhibiting key components of this pathway, such as NEMO or ATM, it may be possible to sensitize cancer cells to DNA-damaging agents, thereby overcoming therapeutic resistance. Ongoing research aims to develop inhibitors that can selectively disrupt this pathway without affecting normal cellular functions[3].

    Understanding the interplay between DNA damage and NF-κB activation is crucial for developing more effective cancer therapies. By elucidating these mechanisms, researchers can identify novel targets to disrupt the survival pathways that cancer cells exploit, potentially leading to improved treatment outcomes.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.